Loading…
Employees: 376
Size SI-BONE (SIBN) is a United States Health Care company (Medical Specialties) with a market value of $1.09B, the 2194th largest of 3,117 United States companies the cockpit tracks. Shares closed at $24.24 on 6 Nov 2026.
Performance Over six months the shares gained 97.6%, against -13.9% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median +11.0%); the operating margin is -7.6% (peer median 7.2%).
Valuation It trades at 4.5× enterprise value to sales against a peer median of 3.4× (10th most expensive of 20).
Capital Return on invested capital runs 24.2 points below its cost of capital (8.0% WACC).
Short interest Short interest is 10.5% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $221M | $201M | $167M | $139M | $106M |
| Revenue growth | — | +20% | +20% | +31% | — |
| Gross profit | $175M | $160M | $132M | $109M | $90.7M |
| EBITDA | -$10.1M | -$16.6M | -$30.9M | -$41.5M | -$56.2M |
| Net income | -$13.7M | -$18.9M | -$30.9M | -$43.3M | -$61.3M |
| Free cash flow | -$4.19M | -$9.09M | -$22.9M | -$26.5M | -$51.2M |
| Capital expenditure | $10.3M | $8.41M | $10.5M | $7.80M | $9.51M |
| Total debt | $42.8M | $36.7M | $37.5M | $39.0M | $39.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SIBN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +28.5% | +0.3% | 3rd highest of 21 |
| 6-month return | +97.6% | -13.9% | highest of 20 |
| Distance from 52-week high | -6.5% | -38.2% | highest of 21 |
| Revenue growth (TTM) | +14.0% | +11.0% | 9th highest of 20 |
| Operating margin | -7.6% | 7.2% | 6th lowest of 20 |
| EV / Sales | 4.5× | 3.4× | 10th most expensive of 20 |
| ROIC minus cost of capital | -24.2 pp | -4.8 pp | 3rd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | 4.5× | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 1.0× | -2.3% | +3.6% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 5.2× | 6.5% | +10.3% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 11.7× | 19.1% | +21.5% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | 26.9× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 3.4× | 12.4% | +12.9% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | 3.4× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 12.8× | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 5.8× | 1.5% | +9.9% |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 6.8× | 10.0% | +8.8% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 2.7× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 2.0× | n/a | n/a |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | 12.7× | 53.9% | +8.6% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | 1.4× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | 3.0× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |